上美股份(02145.HK)盈喜:預期中期利潤同比增加約30.9%至35.8%
格隆匯8月5日丨上美股份(02145.HK)公告,集團截至2025年6月30日止6個月未經審覈綜合管理賬目的初步審閱及對董事會目前可獲得資料的評估,集團預計(i)截至2025年6月30日止6個月的收入約人民幣40.9億元至人民幣41.1億元,同比增加約16.8%至17.3%;及(ii)截至2025年6月30日止6個月的公司利潤約人民幣5.4億元至人民幣5.6億元,同比增加約30.9%至35.8%。
根據目前可得資料,收入及利潤增加主要由於集團科學抗衰護膚品牌韓束全渠道多品類的佈局帶來的收入持續增長及中國嬰童功效護膚品牌newpage一頁的收入同比大幅增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.